BILLEV PHARMA ApS Financials, key figures and credit report
Gross profit 38 801.3 kDKK FY 2025 +24.4% vs 2024
EBIT 13 077.1 kDKK FY 2025 +65% vs 2024
Net debt -8 205.0 kDKK FY 2025 -80.9% vs 2024
Quick ratio 2.9 FY 2025 +0.7 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 30 170.80 | 29 072.53 | 24 763.23 | 31 189.06 | 38 801.27 |
| Costs of management | -22 409.46 | -22 678.60 | -20 406.56 | -23 265.87 | -25 724.13 |
| EBIT | 7 761.34 | 6 393.93 | 4 356.67 | 7 923.18 | 13 077.15 |
| Other financial income | 22.20 | 13.86 | 25.86 | 27.40 | 49.15 |
| Other financial expenses | -62.92 | -65.79 | -40.52 | -46.34 | -29.52 |
| Pre-tax profit | 7 720.62 | 6 342.00 | 4 342.02 | 7 904.25 | 13 096.78 |
| Income taxes | -1 707.46 | -1 398.95 | - 963.48 | -1 760.40 | -2 891.14 |
| Net earnings | 6 013.16 | 4 943.06 | 3 378.54 | 6 143.85 | 10 205.64 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Buildings | 531.61 | ||||
| Machinery and equipment | 5.52 | 2.87 | 14.81 | ||
| Tangible assets total | 5.52 | 2.87 | 14.81 | 531.61 | |
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 4 741.90 | 4 308.44 | 3 900.89 | 6 060.86 | 5 966.01 |
| Prepayments and accrued income | 524.18 | 397.75 | 337.90 | 278.20 | 776.53 |
| Current other receivables | 201.08 | 204.09 | 295.07 | 603.96 | 285.62 |
| Short term receivables total | 5 467.16 | 4 910.28 | 4 533.86 | 6 943.02 | 7 028.16 |
| Other current investments | 161.89 | 163.02 | 174.87 | 188.66 | 223.99 |
| Cash and bank deposits | 4 726.96 | 3 870.32 | 2 187.41 | 5 148.07 | 7 980.99 |
| Cash and cash equivalents | 4 888.86 | 4 033.34 | 2 362.28 | 5 336.73 | 8 204.98 |
| Balance sheet total (assets) | 10 361.53 | 8 946.50 | 6 910.95 | 12 279.75 | 15 764.74 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 320.00 | 320.00 | 320.00 | 320.00 | 320.00 |
| Shares repurchased | 6 013.16 | 4 943.06 | 3 378.54 | 6 143.85 | 10 205.64 |
| Retained earnings | -6 013.16 | -4 943.06 | -3 378.54 | -6 143.85 | -10 205.64 |
| Profit of the financial year | 6 013.16 | 4 943.06 | 3 378.54 | 6 143.85 | 10 205.64 |
| Shareholders equity total | 6 333.16 | 5 263.06 | 3 698.54 | 6 463.85 | 10 525.64 |
| Provisions | 116.53 | 88.14 | 73.82 | 61.21 | 24.04 |
| Non-current deferred tax liabilities | 1 450.86 | 1 361.72 | 606.74 | 259.75 | |
| Non-current liabilities total | 1 450.86 | 1 361.72 | 606.74 | 259.75 | |
| Current trade creditors | 244.16 | 161.00 | 476.60 | 925.50 | 996.61 |
| Current owed to group member | 800.00 | ||||
| Short-term deferred tax liabilities | 15.76 | 1 383.68 | 2 582.33 | ||
| Other non-interest bearing current liabilities | 2 216.82 | 2 056.82 | 2 055.25 | 2 385.76 | 1 636.13 |
| Current liabilities total | 2 460.98 | 2 233.58 | 2 531.85 | 5 494.94 | 5 215.07 |
| Balance sheet total (liabilities) | 10 361.53 | 8 946.50 | 6 910.95 | 12 279.75 | 15 764.74 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated